Sensorion is focused on addressing the treatment needs of millions of patients with debilitating inner ear disorders having limited treatment options. We are committed to delivering break-through, life-transforming therapeutics that improve patients’ quality of life. The drugs that we research and evaluate give us a head start in meeting the unmet medical needs of the significant inner ear market.
Our established network of partners and key opinion leaders is one of our vital assets, fostering strategic market insight. Publicly traded as Euronext Growth (former Alternext Paris) in 2015, Sensorion has a strong balance sheet and an experienced leadership team.